I. MODIFIED AGREEMENTS

Biotech Co.*
(Country;
Symbol)

Biotech Co.*
(Country;
Symbol)

Change from original agreement

Terms/Details (Date)


Crucell NV (the Netherlands; CRXL)

Rhein Biotech NV (the Netherlands; Neuer Markt: RBO)

Converted research collaboration into a commercial license agreement

Crucell's PER.C6 cell line will be used by Rhein for the development and manufacturing of a vaccine against Japanese encephalitis (4/10)

Evotec OAI AG (Germany; Neuer Markt:EVT)

Vertex Pharmaceuticals Inc. (VRTX)

Extended agreement to provide drug discovery chemistry services to Vertex

The contract was extended until the end of June 2002; financial terms were not disclosed (5/15)

InforMax Inc. (INMX)

Axcell Biosciences (subsidiary of Cytogen Corp.; CYTO)

Amended strategic alliance converting the terms from an exclusive license to a nonexclusive license

InforMax has the nonexclusive rights to market, promote and distribute AxCell's ProChart database; each party will have the right to market, distribute, promote and sublicense third-party products in the area of protein-protein interactions (5/3)

II. TERMINATED AGREEMENTS

Bioglan Pharma plc (UK; LSE:BGP)

CeNeS Pharmaceuticals plc (UK; LSE:CEN)

Terminated drug delivery and product development and license agreements

All rights under the agreements are returned to the original owners (4/2)

Biosearch Italia SpA (Italy; Nuovo Mercato:BIO)

IntraBiotics Pharmaceuticals Inc. (IBPI)

Terminated agreement for North American development and commercialization rights to Ramoplanin for topical applications

Biosearch reacquired all rights to oral applications of the drug in May 2001; now it is regaining rights to all topical applications (5/13)

Cambridge Antibody Technology Group plc (UK; CATG; LSE:CAT)

Drug Royalty Corp. Inc. (Canada; TSE:DRI)

Terminated royalty agreement

Cambridge Antibody elected to pay the C$14M (US$9M) termination payment to Drug Royalty through the allotment of 463,818 Cambridge Antibody ordinary shares; the decision to terminate was made after Inwest Investment Ltd. acquired Drug Royalty (5/1)

PPD Discovery (subsidiary of PPD Inc.; PPDI)

Agouron Pharmaceuticals Inc. (unit of Pfizer Inc.)

Terminated research collaboration

PPD will regain research, development and licensing rights to targets for selectively eradicating cancer cells, following a decision by Agouron to conclude the collaboration in June (5/7)


Notes:

# The information in the chart does not cover agricultural agreements.

* Private companies are indicated with an asterisk; unless otherwise noted, stock symbols listed are on the Nasdaq market.

ND = Not disclosed, reported and/or available.

LSE = London Stock Echange; TSE = Toronto Stock Exchange

No Comments